* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBIT Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend
Dec20
Dec21
Dec22
Dec23
EV-to-EBIT
-
-
-16.48
-16.06
Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT Distribution in the Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,736.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-306.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$4,924.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-306.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02315 has been successfully added to your